Navigation Links
Edison Pharma Hits Milestone as A0001 Enters Phase 1 Clinical Development
Date:7/14/2008

"Today we have reached a key milestone in transforming Edison from a discovery to development-stage company," stated Guy Miller, M.D., Ph.D., Chairman and CEO of Edison. "A0001's entry into Phase 1 is the first step in validating Edison's platform and providing needed therapies for patients suffering from rare mitochondrial diseases. As we look toward the future, we expect to focus our energies on refining our approach to treating rare mitochondrial diseases, and expanding our investigation of redox drugs for the treatment of diseases of aging."

About Edison Pharmaceuticals

Edison Pharmaceuticals, Inc. is a biotechnology company based in Silicon Valley California at the San Jose Biocenter with a specialized knowledge in redox biochemistry and drug design. The company is focused on developing drugs for rare mitochondrial diseases that impair energy metabolism, for which there are no FDA-approved treatments. Edison is leveraging its skills in redox biology and chemistry, and data obtained in its inherited mitochondrial disease programs, to discover new therapeutics for diseases commonly associated with aging.


'/>"/>
SOURCE Edison Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. MAP Pharmaceuticals Initiates Phase 3 Clinical Trial in Patients With Migraine
2. VIA Pharmaceuticals Completes Patient Visits in Phase 2 Carotid Endarterectomy (CEA) Trial
3. Cerimon Pharmaceuticals Initiates Phase II Study to Evaluate Simulect(R) (Basiliximab) for Noninfectious Uveitis
4. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
5. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
6. Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
7. Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV
8. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
9. Peregrine Pharmaceuticals Reports Positive Early Results in Phase II Study of Bavituximab in Breast Cancer
10. IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
11. Isis Pharmaceuticals Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... R.I. , July 10, 2014 CVS Caremark ... board of directors has approved a quarterly dividend of $0.275 ... dividend is payable on August 1, 2014, to holders of ... CVS Caremark is dedicated to helping people ... pharmacy company in the United States . ...
(Date:1/15/2014)... Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition of ... Size, Share, Growth, Trends And Forecast, 2013 - 2018" ... http://photos.prnewswire.com/prnh/20130307/600769 ) Dental consumables ... to treat dental impairments, for tooth restoration and in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4
... VRUS ), a clinical stage pharmaceutical company ... treat viral,infections, reported unaudited financial results for the ... Pharmasset reported a net loss,attributable to common stockholders ... first fiscal quarter of 2008, as compared to ...
... Software & Database Developed in West ... Treatment Options, VENLO, Netherlands and GRAND RAPIDS, ... (CMM) today announced the formation of a,collaborative effort ... Prime Standard: QIA) to support research focused on ...
Cached Medicine Technology:Pharmasset Reports First Fiscal Quarter 2008 Financial Results 2Pharmasset Reports First Fiscal Quarter 2008 Financial Results 3Pharmasset Reports First Fiscal Quarter 2008 Financial Results 4Pharmasset Reports First Fiscal Quarter 2008 Financial Results 5Pharmasset Reports First Fiscal Quarter 2008 Financial Results 6Pharmasset Reports First Fiscal Quarter 2008 Financial Results 7Pharmasset Reports First Fiscal Quarter 2008 Financial Results 8QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 2QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 3QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Women's Health Issues 4
(Date:7/10/2014)... Colo. (July 8, 2014) A new study from ... modest improvements, poor oral health remains a major problem ... , "The oral health among Native Americans is abysmal ... rest of the country," said Terrence Batliner, DDS, MBA, ... Research at the School of Public Health. "The number ...
(Date:7/10/2014)... July 10, 2014 (HealthDay News) -- Nature, not nurture, ... of individual chimpanzees, a new study finds. "As ... comes to cognitive [thinking] abilities in chimpanzees," William Hopkins ... said in a news release from the journal ... insight into the evolution of intelligence in humans, Hopkins, ...
(Date:7/10/2014)... 2014 (HealthDay News) -- Adults with dyslexia are more ... children or teenagers than people who don,t have the ... Dyslexia, which affects up to 10 percent of people, ... 35 percent of adults with this condition said they ... percent of those without dyslexia. "Even after accounting ...
(Date:7/10/2014)... Kristen Fischer HealthDay ... Slimming down may help ease the hot flashes that often ... debilitating for more than 50 percent of menopausal women, said ... and reproductive science at the Icahn School of Medicine at ... menopausal women experience more than 10 hot flashes a day, ...
(Date:7/10/2014)... HealthDay Reporter THURSDAY, July ... that break out regularly between outspoken celebrities or loudmouth pundits ... relationship, a new study suggests. High amounts of Twitter ... the couple is in a long-term relationship, according to findings ... turn, that friction can lead to cheating and breakups, the ...
Breaking Medicine News(10 mins):Health News:Study finds widespread oral health problems among Navajo 2Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Researchers See Link Between Dyslexia, Abuse 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Are You Tweeting Your Marriage Away? 2Health News:Are You Tweeting Your Marriage Away? 3
... Patient Care Model Significantly Improves Patient OutcomesEL SEGUNDO, ... provider of kidney care services for those diagnosed ... findings of a study revealing DaVita,s IMPACT(TM) (Incident ... program can significantly reduce mortality rates for new ...
... Pediatric surgeons are able to repair complex heart defects ... but that doesn,t necessarily mean a happy ending for ... great quality of life and others, with the same ... pediatric medical centers throughout the United States shows that ...
... HOUSTON (March 29, 2009) The allergen breathed in by ... MMP7 that activates a cascade of events to prompt an ... College of Medicine ( www.bcm.edu ) in Houston in a ... Immunology . , In particular, MMP7 activates interleukin 25, a ...
... the same for bare metal or drug-eluting devices, study found, ... that stent thrombosis, a blood clot inside a stent, is ... no difference in the clot risk for either drug-eluting ... After a heart attack, many patients undergo a treatment ...
... Health Ltd. affiliate program is the answer for individuals who want to ... benefits as well as demand. ZEO Health has created a risk-free, ... today and find out more about the affiliate program. , ... New ...
... Michael Harbut, M.D., MPH, co-director of the National ... Barbara Ann Karmanos Cancer Institute in Detroit, MI, and ... Wayne State University , announced the use of ... asbestos-related lung disease. The announcement was made at the ...
Cached Medicine News:Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 2Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 3Health News:Physicians mending broken hearts 2Health News:No Increase in Clots With Drug-Eluting Stents 2Health News:No Increase in Clots With Drug-Eluting Stents 3Health News:ZEO Health's New Program Offers Answer for Those Looking for Income 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 2Health News:New Tool in the Radiography Approach Will Assist in Earlier Detection of Asbestos-Related Diseases 3
Nitinol Flat Wire Basket...
A breakaway microwell EIA for the detection of toxins produced by Enterohemorrhagic E. coli...
For presumptive identification of Escherichia coli using enzyme technology. Tests: Indole, MUG...
A single tube that performs two rapid tests for E. coli from culture. ColiScreen™ combines both the indole test with the glucuronidase test to increase the specificity....
Medicine Products: